Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Decision and Details
U.S. patent allowance for a pharmaceutical for cancer treatment
Decision25 September 2026 (date the notice of allowance was received)
Going forwardFor CBA-1205, we aim to out-license the product to pharmaceutical companies using safety and preliminary efficacy data obtained from a domestic Phase 1 clinical trial.
Quantity / scaleU.S. patent application No.17/599,820
Reason
To strengthen the intellectual property foundation supporting our development and out-licensing activities.
Impact on Business Performance
This matter will have no impact on results for the fiscal year ending December 2026.
Title of inventionPharmaceutical for cancer treatment
Patent holderChiome Bioscience Inc.
| Item | Details |
|---|---|
| Matter Covered | U.S. patent allowance for a pharmaceutical for cancer treatment |
| Decision Date | 25 September 2026 (date the notice of allowance was received) |
| Quantity / scale | U.S. patent application No.17/599,820 |
| Impact on Business Performance | This matter will have no impact on results for the fiscal year ending December 2026. |
| Reason | To strengthen the intellectual property foundation supporting our development and out-licensing activities. |
| Future plans | For CBA-1205, we aim to out-license the product to pharmaceutical companies using safety and preliminary efficacy data obtained from a domestic Phase 1 clinical trial. |
| Title of invention | Pharmaceutical for cancer treatment |
| Patent holder | Chiome Bioscience Inc. |
Items this document does not state (6)
Decision-Making BodyImplementation DatePeriod CoveredAmountGoverning RuleRelated previous disclosures
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen the intellectual property foundation supporting our development and out-licensing activities.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.